Blood Research最新文献_第10页

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia. 慢性髓性白血病患者停用伊马替尼、达沙替尼和尼洛替尼后的无治疗缓解。

IF 2.2

Blood Research Pub Date : 2023-04-30 DOI: 10.5045/br.2023.2023035

Jae Joon Han

{"title":"Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia.","authors":"Jae Joon Han","doi":"10.5045/br.2023.2023035","DOIUrl":"https://doi.org/10.5045/br.2023.2023035","url":null,"abstract":"Patients with chronic myeloid leukemia (CML) in the chronic phase receiving tyrosine kinase inhibitor (TKI) therapy are expected to have long-term survival outcomes comparable to those of the general population. Many clinical trials have confirmed that some patients sustain molecular responses without continuing TKI therapy. Treatment-free remission (TFR) is a new goal in treating chronic CML. The safety and outcome of TFR were studied in clinical trials after discontinuing imatinib or the second-generation TKIs dasatinib or nilotinib. TFR was safe in approximately 50% of patients who achieved a deep molecular response to TKI therapy. Patients who relapsed after discontinuing TKI responded immediately to the reintroduction of TKI. The mechanism by which TFR increases the success rate still needs to be understood. The hypothesis that the modulation of immune function and targeting of leukemic stem cells could improve the TFR is under investigation. Despite the remaining questions, the TFR has become a routine consideration for clinicians in the practice of molecular remission in patients with CML.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"58 S1","pages":"S58-S65"},"PeriodicalIF":2.2,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/37/e9/br-58-s1-s58.PMC10133852.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9456506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Mycosis fungoides and Sézary syndrome. 蕈样真菌病和ssamzary综合征。

IF 2.2

Blood Research Pub Date : 2023-04-30 DOI: 10.5045/br.2023.2023023

Hyewon Lee

引用次数: 0

Recent advances in diagnosis and therapy in systemic mastocytosis. 系统性肥大细胞增多症的诊断与治疗进展。

IF 2.2

Blood Research Pub Date : 2023-04-30 DOI: 10.5045/br.2023.2023024

Hyun Jung Lee

{"title":"Recent advances in diagnosis and therapy in systemic mastocytosis.","authors":"Hyun Jung Lee","doi":"10.5045/br.2023.2023024","DOIUrl":"https://doi.org/10.5045/br.2023.2023024","url":null,"abstract":"Mastocytosis is a heterogeneous neoplasm characterized by accumulation of neoplastic mast cells in various organs. There are three main types: cutaneous mastocytosis (CM), systemic mastocytosis (SM), and mast cell sarcoma. CM mainly affects children and is confined to the skin, whereas SM affects adults and is characterized by extracutaneous involvement, with or without cutaneous involvement. Most cases of SM have an indolent clinical course; however, some types of SM have aggressive behavior and a poor prognosis. Recent advances in the understanding of the molecular changes in SM have changed the diagnosis and treatment of aggressive and advanced SM subtypes. The International Consensus Classification and World Health Organization refined the diagnostic criteria and classification of SM as a result of accumulation of clinical experience and advances in molecular diagnostics. Somatic mutations in the KIT gene, most frequently KIT D816V, are detected in 90% of patients with SM. Expression of CD30 and any KIT mutation were introduced as minor diagnostic criteria after the introduction of highly sensitive screening methods. SM has a wide spectrum of clinical features, and only a few drugs are effective at treating advanced SM. Currently, the mainstay of SM treatment is limited to the management of chronic symptoms related to release of mast cell mediators. Small-molecule kinase inhibitors targeting the KIT-downstream and KIT-independent pathways were recently approved for treating advanced SM. I describe recent advances in diagnosis of SM, and review the currently available and emerging therapeutic options for SM management.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"58 S1","pages":"96-108"},"PeriodicalIF":2.2,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5f/82/br-58-s1-s96.PMC10133845.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9723127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel therapeutics for myelofibrosis. 骨髓纤维化的新疗法。

IF 2.2

Blood Research Pub Date : 2023-04-30 DOI: 10.5045/br.2023.2023012

Sung-Eun Lee

{"title":"Novel therapeutics for myelofibrosis.","authors":"Sung-Eun Lee","doi":"10.5045/br.2023.2023012","DOIUrl":"https://doi.org/10.5045/br.2023.2023012","url":null,"abstract":"Myelofibrosis (MF) includes primary MF, post-essential thrombocythemia MF, and post-polycythemia vera MF. MF is a progressive myeloid neoplasm characterized by ineffective clonal hematopoiesis, extramedullary hematopoiesis, a reactive bone marrow environment resulting in reticulin deposition and fibrosis, and a propensity for leukemia transformation. The identification of driver mutations in JAK2, CALR, and MPL has contributed to a better understanding of disease pathogenesis and has led to the development of MF-specific therapies, such as JAK2 inhibitors. Despite the fact that ruxolitinib and fedratinib have been clinically developed and approved, their use is limited due to adverse effects such as anemia and thrombocytopenia. Recently, pacritinib has been approved for a group of thrombocytopenic patients with significant unmet clinical needs. In symptomatic and anemic patients with prior JAK inhibitor exposure, momelotinib was superior to danazol in preventing exacerbation of anemia and in controlling MF-associated signs and symptoms, such as spleen size. Although the development of JAK inhibitors is remarkable, modifying the natural course of the disease remains a priority. Therefore, many novel treatments are currently under clinical development. Agents targeting bromodomain and extra-terminal protein, anti-apoptotic protein Bcl-xL, and phosphatidylinositol-3-kinase delta have been studied in combination with JAK inhibitors. These combinations have been employed in both the frontline and \"add-on\" approaches. In addition, several agents are being studied as monotherapies for ruxolitinib-resistant or -ineligible patients. We reviewed several new MF treatments in the advanced stages of clinical development and treatment options for cytopenic patients.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"58 S1","pages":"S13-S19"},"PeriodicalIF":2.2,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9b/1b/br-58-s1-s13.PMC10133844.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9455554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plasmacytoid dendritic cell neoplasms. 浆细胞样树突状细胞肿瘤。

IF 2.2

Blood Research Pub Date : 2023-04-30 DOI: 10.5045/br.2023.2023052

Yoo Jin Lee, Youjin Kim, Sang Hyuk Park, Jae-Cheol Jo

{"title":"Plasmacytoid dendritic cell neoplasms.","authors":"Yoo Jin Lee, Youjin Kim, Sang Hyuk Park, Jae-Cheol Jo","doi":"10.5045/br.2023.2023052","DOIUrl":"https://doi.org/10.5045/br.2023.2023052","url":null,"abstract":"Plasmacytoid dendritic cells (pDCs) are type I interferon-producing cells that modulate immune responses. There are two types of pDC neoplasms: 1) mature pDC proliferation (MPDCP) associated with myeloid neoplasm and 2) blastic pDC neoplasm (BPDCN). MPDCP is a clonal expansion of mature pDCs that is predominantly associated with chronic myelomonocytic leukemia. In contrast, BPDCN is a clinically aggressive myeloid malignancy involving the skin, bone marrow, lymphatic organs, and central nervous system. There are various types of skin lesions, ranging from solitary brown or violaceous to disseminated cutaneous lesions, which often spread throughout the body. The expression of CD4, CD56, CD123, and pDC markers (TCL-1, TCF4, CD303, and CD304, etc.) are typical immunophenotype of BPDCN. Historically, BPDCN treatment has been based on acute leukemia regimens and allogeneic hematopoietic cell transplantation in selected patients. Recent advances in molecular biology and genetics have led to the development of targeted agents, such as tagraxofusp (a recombinant fusion protein targeting CD123), anti-CD123 CAR-T cells, XmAb14045, and IMGN632. Lastly, this review provides a comprehensive overview of pDC neoplasms.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"58 S1","pages":"90-95"},"PeriodicalIF":2.2,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ed/57/br-58-s1-s90.PMC10133850.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9425922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation. 慢性髓系白血病慢性期一线治疗失败后的治疗包括异基因造血干细胞移植。

IF 2.2

Blood Research Pub Date : 2023-04-30 DOI: 10.5045/br.2023.2023054

Jieun Uhm

引用次数: 1

Prognostication in myeloproliferative neoplasms, including mutational abnormalities. 骨髓增生性肿瘤的预后，包括突变异常。

IF 2.2

Blood Research Pub Date : 2023-04-30 DOI: 10.5045/br.2023.2023038

Junshik Hong

{"title":"Prognostication in myeloproliferative neoplasms, including mutational abnormalities.","authors":"Junshik Hong","doi":"10.5045/br.2023.2023038","DOIUrl":"https://doi.org/10.5045/br.2023.2023038","url":null,"abstract":"Increasing knowledge of the molecular features of myeloproliferative neoplasms (MPNs) is being combined with existing prognostic models based on clinical, laboratory, and cytogenetic information. Mutation-enhanced international prognostic systems (MIPSS) for polycythemia vera (PV) and essential thrombocythemia (ET) have improved prognostic assessments. In the case of overt primary myelofibrosis (PMF), the MIPSS70 and its later revisions (MIPSS70+ and MIPSS70+ version 2.0) effectively predicted the overall survival (OS) of patients. Because post-PV and post-ET myelofibrosis have different biological and clinical courses compared to overt PMF, the myelofibrosis secondary to PV and ET-prognostic model was developed. Although these molecular-inspired prognostic models need to be further validated in future studies, they are expected to improve the prognostic power in patients with MPNs in the molecular era. Efforts are being made to predict survival after the use of specific drugs or allogeneic hematopoietic stem cell transplantation. These treatment outcome prediction models enable the establishment of personalized treatment strategies, thereby improving the OS of patients with MPNs.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"58 S1","pages":"S37-S45"},"PeriodicalIF":2.2,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/44/4e/br-58-s1-s37.PMC10133848.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9510857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Transfusion thresholds: the need for a patient-centered approach in hematologic disorders that require chronic transfusion therapy. 输血阈值:需要以患者为中心的方法在血液疾病，需要慢性输血治疗。

IF 2.2

Blood Research Pub Date : 2023-04-30 DOI: 10.5045/br.2023.2023009

Han Joo Kim, Sang-Hyun Hwang, Heung-Bum Oh, Dae-Hyun Ko

引用次数: 0

Current status of red blood cell manufacturing in 3D culture and bioreactors. 三维培养和生物反应器中红细胞制造的现状。

IF 2.2

Blood Research Pub Date : 2023-04-30 DOI: 10.5045/br.2023.2023008

Soonho Kweon, Suyeon Kim, Eun Jung Baek

引用次数: 0

Lupus anticoagulant hypoprothrombinemia syndrome - could it be a sequelae of COVID-19? 狼疮抗凝血凝血素低原综合征——可能是COVID-19的后遗症吗?